The onboarding of the University of Pennsylvania brings the expertise of leading autism researchers Dr. Heather Nuske and Prof. David Mandel, who will serve as site investigators for the trial. Heather Nuske is a developmental psychologist and Research Assistant Professor of Psychiatry at the Penn Center for Mental Health, whose work focuses on emotional processing and social functioning in children with autism. She has pioneered methods that bridge neuroscience and clinical practice, helping advance precision diagnostics and intervention. David Mandel is Professor of Psychiatry at the Perelman School of Medicine and a leading authority in autism services research and implementation science. Their work focuses on effective and equal deployment of digital health technologies in autism care. Together, Dr. Nuske and Prof. Mandel will bring world-class expertise at the intersection of autism research and digital technology.
Dr. Heather Nuske commented on the collaboration with BlinkLab:
“I am excited to be partnering with BlinkLab to test technology designed to ease the long waitlists that many families need to grapple with as they embark on what is often an exhausting and uncertain road to an autism diagnosis for their child.”
Commenting on the new engagement, BlinkLab Co-founder and CEO, Dr Henk Jan Boele, stated:
“We are delighted to collaborate with the University of Pennsylvania for the main study phase of our FDA registrational trial. The Perelman School of Medicine is one of the world’s foremost centers of excellence in autism research and care. Dr. Nuske and Dr. Mandel are outstanding collaborators who have already contributed invaluable intellectual insights and clinical expertise to our study. Partnering with an Ivy League institution of Penn’s caliber shows BlinkLab’s full commitment to the highest standards of scientific rigor and clinical excellence.”
